Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 5/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.49 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6518510 | 0.98 | S1PR3 (0.50) | S1PR3TRPV4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL26773595 | 0.86 | KDM4E (0.60) | LMNACYP11B2CYP11B1NR3C2SIRT5 | |
| SCHEMBL356343 | 0.85 | CNR2 (0.49) | S1PR3LMNAMAPK1HTTRAB9A | |
| SCHEMBL30452559 | 0.85 | CNR2 (0.49) | S1PR3LMNAMAPK1HTTRAB9A | |
| SCHEMBL2163791 | 0.85 | S1PR3 (0.51) | S1PR3TRPV4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL1953476 | 0.83 | CYP11B2 (0.60) | S1PR3TRPV4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL1274914 | 0.83 | KCNQ3 (0.55) | S1PR3TRPV4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL15464961 | 0.83 | CYP11B2 (0.60) | S1PR3TRPV4KCNQ3KCNQ2KCNE1 | |
| SCHEMBL29472005 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HPGDMRGPRX4 | |
| SCHEMBL4844022 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HPGDMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| US-20110184173-A1 | Pyripyropene Derivatives Having An ACAT2-Inhibiting Activity | THE KITASATO INSTITUTE (JP) | 2011-07-28 | — | — | US | claimed |
| EP-2228376-A1 | PYRIPYROPENE DERIVATIVE HAVING ACAT2-INHIBITING ACTIVITY | The Kitasato Institute (JP) | 2010-09-15 | — | — | EP | claimed |
| EP-1244613-A2 | METHODS FOR PRODUCING CYANOBENZOIC ACID DERIVATIVES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20020072626-A1 | Methods for producing 3-cyano- and 4-cyano-benzoic acid derivative compounds | COR THERAPEUTICS, INC. | 2002-06-13 | — | — | US | claimed |
| WO-2001042198-A2 | METHODS FOR PRODUCING CYANOBENZOIC ACID DERIVATIVES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| CN-122071464-A | Heterocyclic compound, pharmaceutical composition thereof and application thereof | 上海璎黎药业有限公司 | 2026-05-22 | — | — | CN | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2026-01-22 | — | — | US | disclosed |
| US-20250376621-A1 | HALIDE PEROVSKITE NANOCRYSTAL PARTICLES, EMITTERS, MANUFACTURING METHOD THEREOF | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2025-12-11 | — | — | US | disclosed |
| EP-0858451-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997014686-A1 | PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-04-24 | — | — | WO | disclosed |
| US-5595686-A | Silacyclohexane compounds, a liquid crystal composition comprising the same and a liquid crystal device comprising the composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1997-01-21 | — | — | US | disclosed |
| EP-0699683-A1 | Novel silacyclohexane compounds a liquid crystal composition comprising the same and a liquid crystal device comprising the composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072626-A1 | Methods for producing 3-cyano- and 4-cyano-benzoic acid derivative compounds | PFKP, PCCA, TBXAS1 | S1PR3 4423/4885TRPV4 1923/4885KCNQ3 2879/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | S1PR3 529/4885TRPV4 1179/4885KCNQ3 2877/4885 |
| US-20110184173-A1 | Pyripyropene Derivatives Having An ACAT2-Inhibiting Activity | ACAT2, ACAT1, AGPAT2 | S1PR3 2973/4885TRPV4 1118/4885KCNQ3 2055/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | S1PR3 1491/4885TRPV4 1449/4885KCNQ3 505/4885 |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | NAMPT, NAPRT, NNT | S1PR3 965/4885TRPV4 1744/4885KCNQ3 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.